logo
Hibiki Path Advisors Launch a Public Campaign as the Largest Shareholder of JAPAN PURE CHEMICAL CO., LTD.

Hibiki Path Advisors Launch a Public Campaign as the Largest Shareholder of JAPAN PURE CHEMICAL CO., LTD.

Business Wire3 days ago

TOKYO--(BUSINESS WIRE)--Hibiki Path Advisors ('we', 'us', 'our') has decided to launch a public campaign, including shareholder proposals, directed at one of our portfolio companies, JAPAN PURE CHEMICAL CO., LTD. (Securities Code: 4973) (hereinafter referred to as 'the Company', 'JPC'), in the lead-up to its 54 th Annual General Meeting of Shareholders scheduled for 20 th June 2025. As the largest shareholder of the Company, our aim with this campaign is to protect and enhance the common interests of all shareholders.
Opposition to the reappointment of Director and Honorary Advisor Masao Watanabe to the Board
W ith regard to the other director nominees, we plan to oppose the election of eight individuals (including substitute candidates), excluding Mr. Tomoyuki Kojima and Ms. Momoe Kuromatsu (*1)
Plan to oppose the transition to a company with an Audit and Supervisory Committee (*1)
S hareholder proposal (Item 10): Enhancement of stock-based compensation for directors
(excluding outside directors)
S hareholder proposal (Item 11): Partial amendment to the Articles of Incorporation regarding the decision-making body for matters such as surplus dividends
S hareholder proposal (Items 12 and 13): Strengthening of shareholder returns to improve ROE (including share buybacks and increased dividends)
*1 For the rationale behind why items 1. and 2. remain under consideration rather than being finalized, please refer to the attached statement of purpose.
For further details regarding the public campaign, please refer to the statement of purpose via the link below:
" Regarding the Public Campaign as the largest Shareholder of JAPAN PURE CHEMICAL CO., LTD."
We have consistently engaged with the Company over several years earnestly, with our sole intention to guide the Company to take more proactive measures to maximize corporate value. Despite our longstanding, friendly, and earnest proposals since 2018 and the fact that we are currently the largest shareholder holding approximately 18% of the shares (excluding treasury shares) as of the end of March 2025, the Company has completely disregarded our fair requests and abandoned efforts to bridge the differences in opinion. As a result, we have reached the decision to launch a campaign including the submission of shareholder proposals with the aim of protecting the collective interests of all shareholders.
As a premise of this campaign, it is a fact that Board of Directors have the fiduciary duty to act in the best interest of the Company and the shareholders. Despite that, JPC board has been avoiding earnest engagement from the requests of general shareholders, including us as the largest shareholder and this continued management practices neglect their fiduciary duties as well as true advancement of corporate value. In our view, the primary cause of this governance failure lies in two factors. First is the continued dominance of Director/Senior Advisor Masao Watanabe (hereinafter referred to as 'Watanabe'), who has retained effective control of JPC for approximately 25 years since the Company's MBO, despite completely failing to generate corporate value during his term. Second is the uniquely structured board of directors (including independent directors), where repeated appointments from limited corporate groups have created conditions that hinder effective oversight.
Despite such governance failure, we find it utterly disappointing for the JPC Board of Directors' intention to propose again for the reappointment of Watanabe in this year's General Meeting of Shareholders but additionally establish an Audit and Supervisory Committee structure that appears to significantly delegate authority to internal executive directors which appear to potentially further strengthen Watanabe's de facto control. The company has tried to persist with a board composition that appears to be a continuation of the existing structure, which demonstrates not only a complete lack of reflection on the prolonged destruction of corporate value but also a troubling unwillingness to listen to the legitimate voices of shareholders. Under the banner of a so-called "second founder," the Company has effectively deified Watanabe, thereby forfeiting a critical opportunity for fundamental transformation.
We observe that there is serious lacking in fiduciary duty of the Company's Board of Directors as the Company's prolonged underperformance while continuing to implement piecemeal measures and deferring fundamental decisions. Not only did the Company Board of Directors fail to uphold common interests of shareholders, they also undermined the Company's competitive advantage and value creation. Such inaction ultimately harms all stakeholders, including customer relationships and the livelihoods of employees committed to the Company.
We respectfully ask our fellow shareholders to support our proposal to enhance and maximize the common interests of all shareholders. Furthermore, we urge you, as fellow shareholders, to carefully consider whether the company's proposals – including the amendment of the Articles of Incorporation to transition to a company with an Audit and Supervisory Committee, and the election of directors, truly contribute to the fundamental enhancement of the company's corporate value, and so we urge you to exercise your shareholder rights with sound and thoughtful judgment.
Note: This post does not constitute a solicitation for an offer to acquire or recommend the purchase or sale of specific securities, or advice on investment, legal, tax, accounting, or any other matters. In the event of any discrepancy or conflict between the English and Japanese versions, unless otherwise noted, the meaning of the Japanese language version shall prevail unless otherwise expressly indicated.
Sincerely yours,

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Century Plyboards (India) Ltd (BOM:532548) Q4 2025 Earnings Call Highlights: Strong Revenue ...
Century Plyboards (India) Ltd (BOM:532548) Q4 2025 Earnings Call Highlights: Strong Revenue ...

Yahoo

time9 hours ago

  • Yahoo

Century Plyboards (India) Ltd (BOM:532548) Q4 2025 Earnings Call Highlights: Strong Revenue ...

Release Date: June 02, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Century Plyboards (India) Ltd (BOM:532548) reported a year-on-year revenue growth of 13% on a consolidated basis for Q4 FY25. The plywood segment is performing well, with a revenue increase of 9.8% year-on-year and an EBITDA margin of 15.4% for the quarter. The company's Andhra Pradesh facility is scaling up, expected to support sales growth in the laminate segment. MDF segment revenue grew by 37.5% with an EBITDA margin of 13.2%, indicating strong performance. The company is optimistic about future growth, with plans to expand capacity in the plywood and laminate segments. The particle board segment is under pressure, with a revenue decline of 23.2% in Q4 and an EBITDA margin of only 5.6%. The laminate segment faced margin pressure due to higher schemes and increased sales overheads, resulting in a standalone EBITDA margin of 5.6%. There is significant overcapacity in the MDF market, leading to pricing pressure and reduced margins. The company has seen a significant jump in inventory days, impacting working capital. Export margins are under pressure due to substantial pricing pressure in the international MDF market. Warning! GuruFocus has detected 7 Warning Signs with BOM:532548. Q: Can you provide details on the EPCG scheme benefits for the MDF plant and the export obligations? A: The EPCG benefits can be availed over six years, with export obligations ranging from INR 150 crore to INR 400 crore, depending on GST considerations. Export viability varies annually, and we are currently exporting to the Middle East, although pricing pressures have limited volumes. Unidentified_5 Q: Are there any expected price changes in the MDF segment? A: We anticipate price hikes in MDF, but it's too early to confirm. We expect some price increases towards the end of the year. Unidentified_5 Q: What is the current capacity and future expansion plans for the plywood segment? A: The current capacity utilization is about 90%. We plan to add 48,000 CBM at the Huharur plant in the next 15 months, with additional expansions planned for other facilities. Unidentified_6 Q: How do you view the opportunity for Indian laminate manufacturers in the global market? A: India remains a favorable destination for laminate exports due to labor cost advantages and manufacturing efficiency. We have been white labeling for international brands, and the opportunity in compact laminates is substantial. Unidentified_5 Q: What are the reasons for the decline in particle board segment revenue and margins? A: The decline is due to increased timber costs and stagnant realizations. Overcapacity and imports have pressured prices. The new plant in Tamil Nadu is expected to improve margins with lower production costs. Unidentified_5 For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio

Celebrating 20th Anniversary and Connecting with the Automotive Industry--Registration Open for AMTS 2025 (July 9 to 11, 2025)
Celebrating 20th Anniversary and Connecting with the Automotive Industry--Registration Open for AMTS 2025 (July 9 to 11, 2025)

Yahoo

time14 hours ago

  • Yahoo

Celebrating 20th Anniversary and Connecting with the Automotive Industry--Registration Open for AMTS 2025 (July 9 to 11, 2025)

SHANGHAI, June 3, 2025 /PRNewswire/ -- RX Hengjin (Shanghai) Co., Ltd. announces that the leading professional exhibition in the automotive engineering industry - Shanghai International Automotive Manufacturing Technology & Material Show (AMTS 2025), which is held from July 9 to 11, 2025, at Shanghai New International Expo Center. It is an ideal platform for international companies to enter the automotive manufacturing market of China, to introduce the latest technology and meet with key industry players from auto OEMs, system integrators, tier 1&2 suppliers, vehicle and component R&D and manufacturing facilities. Registration is now open ( Shaping the Future Automotive with Technology AMTS showcases a diverse range of products and solutions in automotive manufacturing including car body stamping, welding and joining, painting, automotive assembly, auto parts machining engineering, assembly and testing, automotive materials and design, automotive development and trial production, intelligent production line logistics, quality control and testing and other fields. Keeping up with the trend of new energy vehicles, the exhibition will focus on the innovative design and manufacturing processes of auto parts for new energy vehicles, such as EV battery manufacturing, motor and electronic control production, lightweight material application, and intelligent driving technology. In 2025, the event will mark its 20th anniversary, bringing together 800+ exhibitors, 70,000+ industry professionals from around the world. Why Visit the AMTS 2025? Connect with Leading System Integrators and Tier 1/2 Suppliers in the Automotive Industry This event offers unparalleled networking opportunities with leading system integrators and Tier 1 and 2 suppliers, allowing attendees to build important business connections. Visitors can explore advancements in electric vehicle manufacturing and gain insights into cutting-edge technologies driving the future of the automotive world. AMTS 2025 also provides a unique opportunity for global automotive enterprises to explore China's New Energy and Intelligent Vehicle Manufacturing through the Business Exploration Tour. Concurrent events cover every aspect of automotive manufacturing and delve deeply into industry trends, making AMTS 2025 a must-visit for anyone interested in the future of automotive engineering. Accompany Programs Unlock the Future of Smart Mobility AMTS 2025 features a wide range of programs and events focused on the future of smart mobility. Attendees can participate in the New Energy Vehicle Engineering 2025 exchange, which focuses on development opportunities in overseas markets with over 1,000 industry professionals. The Future Car Engineering 2025 program provides opportunities for exchange through design, R&D, and intelligent automotive technology. The event also includes 20 onsite workshops and forums covering assembly technology, new energy car components, forming technology, and testing and validation technology. Additionally, the Business Tour offers visits to leading companies such as BYD and SAIC, as well as prominent Tier 1 and 2 suppliers and parts factories. With overseas events and the AMTS 20th anniversary and A+ Awards ceremony, AMTS 2025 is a must-visit for anyone interested in the latest advancements and future trends in automotive engineering. View original content to download multimedia: SOURCE RX Hengjin (Shanghai) Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

2025 ASCO |Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
2025 ASCO |Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer

Yahoo

time21 hours ago

  • Yahoo

2025 ASCO |Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer

YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating the efficacy and safety of disitamab vedotin (DV), developed by Remegen Co., Ltd., and toripalimab (PD-1) combined with CAPOX or trastuzumab as the first-line therapy for HER2-expressing patients with locally advanced or metastatic (la/m) gastric cancer. Comparing to the control group who received standard-of-care therapy, the DV combination therapy demonstrated clinically meaningful efficacy improvement, potentially to benefit patients who are non-responders to traditional targeted therapies. The data presented are from the Phase 2 part of a randomized, multi-cohort, seamlessly connecting Phase 2/3 study, which enrolled systematic chemotherapy-native patients with different HER2 expression levels. As of April 7, 2025, the results showed: Among HER2-overexpressing gastric cancer patients, compared to the PD-1-trastuzumab-CAPOX combination therapy, DV and PD-1 + chemotherapy as well as DV and PD-1 + trastuzumab both demonstrated statistically significant efficacy and favorable safety profiles. Objective response rate (ORR): 66.7% vs 82.4% vs 68.8%; Median progression-free survival (mPFS): NR vs NR vs 14.1 months, with risk of disease progression decreasing by 54%(HR=0.46)and 41% (HR: 0.59); 12-month PFS rate: 66.3%, 67% and 53.6%; Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc. In patients with HER2-low-expressing gastric cancer, promising efficacy was observed with DV + PD-1 + CAPOX comparing to PD-1 + CAPOX, with a manageable safety profile. ORR: 72.0% vs 47.8%; mPFS: 9.9 vs 7.2 months, with risk of disease progression decreasing by 31% (HR: 0.69); Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc. Dose optimization conducted in patients with HER2-median/low-expressing gastric cancer. Compared to PD-1 + CAPOX, DV at 2.5 mg/kg or 2.0 mg/kg combined with PD-1 + reduced-dose CAPOX showed significant efficacy, and better safety over the full-dose chemotherapy. ORR: 71.4% vs 66.7% vs 56.3%; 6-month PFS rate: 71.4%,72.7% and 53.3%. Globally, this is the first study to explore the triple combination therapy of "HER2 ADC + PD-1 + targeted medication" as first-line treatment of patients with la/m gastric cancer, pioneering a new mode of synergistic therapy. The multi-cohort design of this study provides precision treatment regimen for gastric cancer patients with different level of HER2 expression. For the HER2-overexpressing gastric cancer patients, DV + PD-1 + trastuzumab has the potential to become the new standard first-line treatment; for the HER2-low-expressing gastric cancer patients, DV + PD-1 + chemotherapy has the potential to fill the treatment gap of these patients. Based on the data obtained from the phase 2 study, the phase 3 clinical study of the triple combination therapy in patients with HER2-median/low-expressing gastric cancer has been initiated in April, 2025, in which 616 participants were planned to be enrolled, to further validate the efficacy of the DV combination therapy. Gastric cancer is the fifth most common malignant tumor in the world, and China accounts for about 42.6% of new cases and 45.0% of deaths worldwide. HER2 is an important target in the treatment of gastric cancer, while the traditional targeted drug trastuzumab is only effective in the population with high expression (IHC 3+ or IHC 2+/FISH+), and can easily become resistant. There is a lack of effective targeted therapy options for patients with low/median HER2 expression (IHC 1+ or IHC 2+/FISH-), and the efficacy of chemotherapy combined with immunotherapy is not satisfactory. As the first domestic HER2-targeted ADC drug in China, DV not only precisely kills tumor cells with HER2 over expression but also attacks adjacent cells with HER2 low expression through the bystander effect. Preclinical studies have also shown that the combination of DV with PD-1 inhibitor and trastuzumab can enhance anti-tumor activity. View original content to download multimedia: SOURCE RemeGen Co., Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store